Excerpted from Reuters Selenomethionine treatment of certain high-risk patients can protect against the development of esophageal squamous cell cancer (ESCC), according to a report in the September issue of Gastroenterology Dr. Paul J. Limburg from Mayo Clinic College of Medicine, Rochester, Minnesota and colleagues tested the chemoprevention potential of selenomethionine (a synthetic form of organic selenium) and celecoxib (a selective inhibitor of COX-2) in 238 asymptomatic adults with histologically confirmed mild or moderate esophageal squamous dysplasia. In the overall analysis, neither selenomethionine nor celecoxib significantly changed the dysplasia grade during the course of the trial. However, patients treated with selenomethionine showed a trend toward increased regression and decreased progression, the report indicates, but no such trend was seen with celecoxib treatment. Gastroenterology 2005;129:863-873. Int J Cancer, 8/07 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.